- Meeting abstract
- Published:
The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
Arthritis Research & Therapy volume 4, Article number: 72 (2002)
Background
Rheumatoid arthritis (RA) patients are successfully treated with infliximab (anti-TNF-α therapy). This therapy may induce autoantibodies like anti-dsDNA antibodies.
Objectives
To investigate the effect of infliximab on rheumatoid factor (RF) and anti-citrullinated cyclic peptide antibodies (anti-CCP antibodies).
Patients and methods
62 patients with refractory RA were treated with infliximab in an early access program. They received 3 mg/kg infliximab IV at week 0, 2, 6 and every 8 weeks thereafter in combination with MTX. Serum samples were obtained at baseline and week 30. Samples were tested for RF Waaler-Rose (SERODIA-RA, Fujirebio Inc), RF Latex Fixation (DifcoLaboratories) and anti-CCP antibodies ELISA (Euro-Diagnostica).
Results
At baseline, 41/62 RA patients were positive for RF Waaler-Rose, 39/62 RA patients were positive for RF Latex Fixation and 41/62 RA patients had a positive test result for anti-CCP antibodies ELISA. After infliximab treatment, 33/62 RA patients were positive for RF Waaler-Rose, 31/62 RA patients were positive for RF Latex Fixation and we observed a positive test result for anti-CCP antibodies in the same 41/62 RA patients. McNemar test revealed a significant paired difference for RF Waaler-Rose (P = 0.039) and for RF Latex Fixation (P = 0.021), but not for anti-CCP antibodies (P = 1.0). Wilcoxon Signed Rank Test showed a significant decrease for RF Waaler-Rose (P < 0.001) and for RF Latex Fixation (P = 0.035). No significant difference was observed for anti-CCP antibodies (P = 0.744).
Conclusion
In RA patients, infliximab treatment results in a decrease of RF Waaler-Rose and RF Latex Fixation. No difference considering the anti-CCP antibodies is seen.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Damme, N., de Rycke, L., Kruithof, E. et al. The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies. Arthritis Res Ther 4 (Suppl 1), 72 (2002). https://doi.org/10.1186/ar517
Received:
Published:
DOI: https://doi.org/10.1186/ar517
Keywords
- Peptide
- Rheumatoid Arthritis
- Arthritis
- Serum Sample
- Infliximab